series-a
Stage
1
Investors
About
ZZ Biotech develops genetically engineered therapeutic proteins, including 3K3A-APC, a variant of human activated protein C optimized for therapeutic use, focusing on wound therapies through licensing agreements with biotech companies such as Dermatherix.
Explore ZZ Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.